How did the CSL share price fare in May?

The biotechnology company's share price was affected by the attention it received from several brokers.

| More on:
woman testing substance in laboratory dish, csl share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

How did the CSL Limited (ASX: CSL) share price fare over the month of May? Good question!

The CSL share price has certainly had a rocky 12 months or so, despite the fact that it's trading at almost the same level today as it was exactly a year ago. Over the past 12 months, CSL shares have bounced around the ASX, trading for as high as $320 and as low as $242.

But what of the month just gone? Well, CSL started May at $271.16 a share and ended the month at $290.47. That puts the company's May gains at 7.12%. Objectively, not a bad performance for one month. For some perspective, the S&P/ASX 200 Index (ASX: XJO) managed a gain of 1.9% over the same period.

May news

So what happened in May over at CSL? Well, not too much news came out of the healthcare giant last month. Perhaps the most significant item of interest came early on. Back on 6 May, CSL announced that the company is pressing ahead with a commercialisation and license agreement with Uniqure NV (NASDAQ: QURE). Uniqure is a company that is developing a treatment called etranacogene dezaparvovec (or AMT-061) to treat haemophilia B.

Under the deal, CSL will have the rights to commercialise and sell AMT-061 if all goes to plan. However, investors didn't seem too chuffed at the idea at the time and sent CSL shares down on the day this was announced. By the end of the month, it didn't seem like much of a market-mover though.

A factor that was clearly playing in CSL's favour though was the attention it received from brokers and fundies over May. The Motley Fool covered several fund managers and brokers who all gave bullish opinions on the CSL share price over the month. These included brokers Citi and Credit Suisse, as well as fundie Michael Wayne of Medallion Financial.

About the CSL share price

As we discussed earlier, CSL has had a bumpy year, despite the parity of the current share price to where it was 12 months ago. But before the COVID market crash of last year, CSL was one of the best ASX 200 blue chips to own. It rose almost 200% between June 2016 and February 2020, when it hit its current all-time high of $336 a share. Even on today's levels, CSL remains around 15% off of that all-time high.

On current pricing, CSL shares have a market capitalisation of $130 billion, a price-to-earnings (P/E) ratio of 37.78 and a trailing dividend yield of 0.99%.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »